<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lorazepam - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Lorazepam</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üò¥ Lorazepam</h1>
        <h2 class="chemical-name">7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Lorazepam" 
                data-category="Depressants" 
                data-chemical="7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Ativan</span> ‚Ä¢ <span>Temesta</span> ‚Ä¢ <span>Tavor</span> ‚Ä¢ <span>Lorafen</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Benzos</span> ‚Ä¢ <span>Downers</span> ‚Ä¢ <span>Tranks</span> ‚Ä¢ <span>Bars</span> ‚Ä¢ <span>Lories</span>
            </div>
            <div class="name-category">
              <h4>Medical/Clinical</h4>
              <span>Anxiolytic</span> ‚Ä¢ <span>Sedative-hypnotic</span> ‚Ä¢ <span>Anticonvulsant</span>
            </div>
            <div class="name-category">
              <h4>Chemical Class</h4>
              <span>Benzodiazepine</span> ‚Ä¢ <span>GABA-A agonist</span> ‚Ä¢ <span>3-hydroxybenzodiazepine</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status schedule-4">Schedule IV</span>
          <span class="duration medium">6-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/lorazepam.jpg" alt="Lorazepam tablets" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÖH‚ÇÅ‚ÇÄCl‚ÇÇN‚ÇÇO‚ÇÇ</p>
            <p>MW: 321.16 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Lorazepam</h4>
          <ul>
            <li><strong>Appearance:</strong> Small white, scored tablets (0.5mg, 1mg, 2mg)</li>
            <li><strong>Shape:</strong> Round or oval, often with manufacturer markings</li>
            <li><strong>Texture:</strong> Hard, smooth pharmaceutical tablets</li>
            <li><strong>Odor:</strong> Odorless or very faint medicinal smell</li>
            <li><strong>Taste:</strong> Bitter, chalky taste characteristic of benzodiazepines</li>
            <li><strong>Solubility:</strong> Poorly water-soluble, dissolves in alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Formulations</h4>
          <ul>
            <li><strong>0.5mg tablets:</strong> White, round, scored (lowest therapeutic dose)</li>
            <li><strong>1mg tablets:</strong> White, round, scored (standard anxiety dose)</li>
            <li><strong>2mg tablets:</strong> White, round or oval, scored (maximum single dose)</li>
            <li><strong>Injectable:</strong> Clear solution for medical emergencies (IV/IM)</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Counterfeit Warning</h4>
          <p><strong>Press pills:</strong> Illegal markets may contain fentanyl, other benzos, or inert fillers</p>
          <p><strong>Verification:</strong> Legitimate tablets have consistent markings, proper hardness</p>
          <p><strong>Risk:</strong> Counterfeit benzos may contain lethal adulterants like fentanyl</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">0.25-0.5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">0.5-1mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">1-2mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">2-4mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">4mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosage Guidelines</h4>
        <ul>
          <li><strong>Anxiety disorders:</strong> 0.5-2mg 2-3 times daily as needed</li>
          <li><strong>Insomnia:</strong> 2-4mg at bedtime (short-term use only)</li>
          <li><strong>Panic attacks:</strong> 0.5-2mg during acute episodes</li>
          <li><strong>Elderly patients:</strong> Start with 0.25-0.5mg (increased sensitivity)</li>
          <li><strong>Maximum daily:</strong> Usually not exceeding 10mg in divided doses</li>
          <li><strong>Duration:</strong> Prescribed for shortest effective period (2-4 weeks)</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> Lorazepam has high addiction potential. Never exceed prescribed doses. Tolerance develops rapidly, leading to dose escalation and physical dependence.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-0:45</span>
          <span class="effect">Onset - initial relaxation, reduced anxiety</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-2:00</span>
          <span class="effect">Peak - maximum anxiolytic and sedative effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-6:00</span>
          <span class="effect">Plateau - sustained anxiety relief and sedation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-12:00</span>
          <span class="effect">Comedown - gradual return to baseline anxiety levels</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Profound anxiety reduction</li>
            <li>Muscle relaxation and tension relief</li>
            <li>Sedation and sleep induction</li>
            <li>Anticonvulsant properties</li>
            <li>Emotional blunting and detachment</li>
            <li>Rapid panic attack termination</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Side Effects</h4>
          <ul>
            <li>Drowsiness and fatigue</li>
            <li>Cognitive impairment and confusion</li>
            <li>Memory problems (anterograde amnesia)</li>
            <li>Motor coordination issues</li>
            <li>Emotional numbness</li>
            <li>Rebound anxiety upon discontinuation</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Lorazepam is a positive allosteric modulator of GABA-A receptors, the brain's primary inhibitory neurotransmitter system. It binds to the benzodiazepine binding site on GABA-A receptors, enhancing the effect of GABA by increasing the frequency of chloride channel opening. This results in increased neuronal inhibition, producing anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A receptors</strong></span>
            <span class="affinity">High affinity positive allosteric modulator</span>
            <span class="function">Primary anxiolytic, sedative, and anticonvulsant effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±1 subunit GABA-A</strong></span>
            <span class="affinity">High selectivity</span>
            <span class="function">Sedation, amnesia, motor impairment</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±2/Œ±3 subunit GABA-A</strong></span>
            <span class="affinity">Moderate selectivity</span>
            <span class="function">Anxiolytic effects, muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±5 subunit GABA-A</strong></span>
            <span class="affinity">Lower selectivity</span>
            <span class="function">Memory formation impairment</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Glycine receptors</strong></span>
            <span class="affinity">Weak positive modulation</span>
            <span class="function">Additional muscle relaxation</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic glucuronidation (Phase II metabolism)</p>
          <p><strong>Metabolites:</strong> Lorazepam glucuronide (inactive, rapidly excreted)</p>
          <p><strong>Half-life:</strong> 10-20 hours (intermediate-acting benzodiazepine)</p>
          <p><strong>Bioavailability:</strong> 90-95% oral (excellent absorption)</p>
          <p><strong>Peak plasma:</strong> 1-2 hours after oral dose</p>
          <p><strong>Onset:</strong> 15-45 minutes oral, 1-5 minutes IV</p>
          <p><strong>Protein binding:</strong> 85% bound to plasma proteins</p>
        </div>

        <h4>Neuroadaptation & Dependence</h4>
        <div class="neurotoxicity-info">
          <p><strong>Tolerance:</strong> Develops within days to weeks, requiring dose increases</p>
          <p><strong>Physical dependence:</strong> Occurs with regular use for 2-4 weeks</p>
          <p><strong>Withdrawal syndrome:</strong> Potentially life-threatening seizures and delirium</p>
          <p><strong>GABA downregulation:</strong> Chronic use reduces natural GABA production</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>No active metabolites:</strong> Cleaner elimination compared to other benzos</li>
          <li><strong>Intermediate duration:</strong> Longer than alprazolam, shorter than diazepam</li>
          <li><strong>High potency:</strong> Effective at relatively low doses (milligram range)</li>
          <li><strong>Excellent bioavailability:</strong> Nearly complete oral absorption</li>
          <li><strong>Rapid onset:</strong> Quick relief for acute anxiety and panic</li>
          <li><strong>Predictable kinetics:</strong> Less variable between individuals</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Fatal when combined with alcohol/opioids</li>
            <li><strong>Physical dependence:</strong> Develops rapidly with regular use</li>
            <li><strong>Withdrawal seizures:</strong> Abrupt discontinuation can be fatal</li>
            <li><strong>Memory impairment:</strong> Severe amnesia, especially at higher doses</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li>Never combine with alcohol, opioids, or other depressants</li>
            <li>Don't drive or operate machinery</li>
            <li>Use lowest effective dose for shortest time possible</li>
            <li>Taper gradually when discontinuing - never stop abruptly</li>
            <li>Store securely - high theft and abuse potential</li>
            <li>Don't share medications or take others' prescriptions</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Sleep apnea, severe respiratory depression, acute narrow-angle glaucoma, severe liver disease, pregnancy (especially first trimester), or a history of substance abuse.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>Alcohol:</strong> Severe CNS depression, respiratory failure, death</li>
            <li><strong>Opioids:</strong> Respiratory depression, overdose risk, high fatality rate</li>
            <li><strong>Barbiturates:</strong> Additive CNS depression, respiratory depression</li>
            <li><strong>GHB/GBL:</strong> Severe sedation, respiratory depression, coma</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Other benzos:</strong> Additive effects, increased overdose risk</li>
            <li><strong>Z-drugs:</strong> Zolpidem, zopiclone - enhanced sedation</li>
            <li><strong>Muscle relaxants:</strong> Baclofen, carisoprodol - increased impairment</li>
            <li><strong>Antihistamines:</strong> Enhanced sedation, cognitive impairment</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Antidepressants:</strong> SSRIs may increase lorazepam levels</li>
            <li><strong>Anticonvulsants:</strong> May affect seizure threshold</li>
            <li><strong>Blood pressure meds:</strong> Enhanced hypotensive effects</li>
            <li><strong>Grapefruit juice:</strong> May increase absorption and effects</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule IV</strong> - Prescription only, lower abuse potential than Schedule I-III. Possession without prescription is illegal. Prescriptions limited to 6 months.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class C, Schedule 4</strong> - Prescription only medicine. Possession without prescription can result in arrest.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>Schedule IV</strong> - Controlled substance requiring prescription. Similar regulations to other benzodiazepines.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 4</strong> - Prescription only medicine with restricted access and monitoring requirements.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Uses</h4>
          <p><strong>FDA-approved indications:</strong> Anxiety disorders, insomnia (short-term), preoperative sedation, status epilepticus, alcohol withdrawal syndrome, and panic disorder.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1963</span>
          <p>Lorazepam first synthesized by Wyeth Pharmaceuticals</p>
        </div>
        <div class="history-event">
          <span class="year">1977</span>
          <p>FDA approval for anxiety disorders and insomnia treatment</p>
        </div>
        <div class="history-event">
          <span class="year">1980s</span>
          <p>Becomes widely prescribed, establishing Ativan as major brand</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Recognition of dependence potential leads to prescribing restrictions</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Generic versions become available, reducing cost barriers</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Increased awareness of "benzo epidemic" and withdrawal difficulties</p>
        </div>
        <div class="history-event">
          <span class="year">2020s</span>
          <p>Renewed focus on safe prescribing and gradual tapering protocols</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Medical Impact</h4>
        <p>Lorazepam became one of the most prescribed anti-anxiety medications, offering rapid relief for millions suffering from anxiety disorders. However, its widespread use also contributed to the "benzodiazepine epidemic," highlighting the need for careful prescribing practices and patient education about dependence risks.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>PTSD and Trauma</h4>
          <p>Research into optimal benzodiazepine use in trauma patients, balancing symptom relief with potential memory consolidation interference.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Management</h4>
          <p>Development of safer tapering protocols and medications to ease benzodiazepine withdrawal syndrome.</p>
        </div>
        
        <div class="research-item">
          <h4>Precision Medicine</h4>
          <p>Genetic testing to predict individual responses and optimize dosing based on metabolism variations.</p>
        </div>
        
        <div class="research-item">
          <h4>Alternative Anxiolytics</h4>
          <p>Research into non-benzodiazepine alternatives that provide anxiety relief without dependence potential.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.fda.gov/">FDA</a> - Official prescribing information and warnings</li>
          <li><a href="https://www.drugs.com/">Drugs.com</a> - Patient information and interactions</li>
          <li><a href="https://www.rxlist.com/">RxList</a> - Comprehensive medication guide</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Recovery</h4>
        <ul>
          <li><a href="https://www.benzoinfo.com/">BenzoInfo</a> - Withdrawal support and information</li>
          <li><a href="https://www.benzosupport.org/">Benzo Support</a> - Community for withdrawal recovery</li>
          <li><a href="https://www.reddit.com/r/benzorecovery">/r/benzorecovery</a> - Reddit support community</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><a href="https://www.ashtonmanual.org/">The Ashton Manual</a> - Comprehensive withdrawal guide</li>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Substance abuse treatment locator</li>
          <li><a href="https://www.nami.org/">NAMI</a> - Mental health support and education</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>